#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Biofilms
1-1	0-2	3.	substance[1]	new[1]	coref	6-3[0_1]
1-2	3-11	Biofilms	substance[1]	new[1]	_	_

#Text=As mentioned above , the most common problems of stents are due to their clogging due to the formation of biofilm and adhesion of biological substances that pass through the stent .
2-1	12-14	As	_	_	_	_
2-2	15-24	mentioned	_	_	_	_
2-3	25-30	above	_	_	_	_
2-4	31-32	,	_	_	_	_
2-5	33-36	the	abstract[2]	new[2]	_	_
2-6	37-41	most	abstract[2]	new[2]	_	_
2-7	42-48	common	abstract[2]	new[2]	_	_
2-8	49-57	problems	abstract[2]	new[2]	_	_
2-9	58-60	of	abstract[2]	new[2]	_	_
2-10	61-67	stents	abstract[2]|object	new[2]|new	ana	2-14
2-11	68-71	are	_	_	_	_
2-12	72-75	due	_	_	_	_
2-13	76-78	to	_	_	_	_
2-14	79-84	their	object|abstract[5]	giv|new[5]	coref	15-11
2-15	85-93	clogging	abstract[5]	new[5]	_	_
2-16	94-97	due	abstract[5]	new[5]	_	_
2-17	98-100	to	_	_	_	_
2-18	101-104	the	abstract[6]	new[6]	_	_
2-19	105-114	formation	abstract[6]	new[6]	_	_
2-20	115-117	of	abstract[6]	new[6]	_	_
2-21	118-125	biofilm	abstract[6]|substance	new[6]|new	coref	3-1
2-22	126-129	and	abstract[6]	new[6]	_	_
2-23	130-138	adhesion	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-24	139-141	of	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-25	142-152	biological	abstract[6]|abstract[8]|substance[9]	new[6]|new[8]|new[9]	coref	8-11[44_9]
2-26	153-163	substances	abstract[6]|abstract[8]|substance[9]	new[6]|new[8]|new[9]	_	_
2-27	164-168	that	_	_	_	_
2-28	169-173	pass	_	_	_	_
2-29	174-181	through	_	_	_	_
2-30	182-185	the	object[10]	new[10]	_	_
2-31	186-191	stent	object[10]	new[10]	_	_
2-32	192-193	.	_	_	_	_

#Text=Biofilm represents the most widespread way of microbial growth in nature and is critical for the development of clinical infections .
3-1	194-201	Biofilm	substance	giv	ana	4-1
3-2	202-212	represents	_	_	_	_
3-3	213-216	the	abstract[12]	new[12]	_	_
3-4	217-221	most	abstract[12]	new[12]	_	_
3-5	222-232	widespread	abstract[12]	new[12]	_	_
3-6	233-236	way	abstract[12]	new[12]	_	_
3-7	237-239	of	abstract[12]	new[12]	_	_
3-8	240-249	microbial	abstract[12]|abstract[13]	new[12]|new[13]	coref	16-20[80_13]
3-9	250-256	growth	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-10	257-259	in	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-11	260-266	nature	abstract[12]|abstract[13]|abstract	new[12]|new[13]|new	_	_
3-12	267-270	and	_	_	_	_
3-13	271-273	is	_	_	_	_
3-14	274-282	critical	_	_	_	_
3-15	283-286	for	_	_	_	_
3-16	287-290	the	event[15]	new[15]	_	_
3-17	291-302	development	event[15]	new[15]	_	_
3-18	303-305	of	event[15]	new[15]	_	_
3-19	306-314	clinical	event[15]|abstract[16]	new[15]|new[16]	coref	19-9[100_16]
3-20	315-325	infections	event[15]|abstract[16]	new[15]|new[16]	_	_
3-21	326-327	.	_	_	_	_

#Text=It is produced by bacteria and host products that tend to adhere to different surfaces .
4-1	328-330	It	substance	giv	coref	6-10
4-2	331-333	is	_	_	_	_
4-3	334-342	produced	_	_	_	_
4-4	343-345	by	_	_	_	_
4-5	346-354	bacteria	animal	new	coref	6-27
4-6	355-358	and	_	_	_	_
4-7	359-363	host	_	_	_	_
4-8	364-372	products	abstract	new	ana	5-1
4-9	373-377	that	_	_	_	_
4-10	378-382	tend	_	_	_	_
4-11	383-385	to	_	_	_	_
4-12	386-392	adhere	_	_	_	_
4-13	393-395	to	_	_	_	_
4-14	396-405	different	place[20]	new[20]	_	_
4-15	406-414	surfaces	place[20]	new[20]	_	_
4-16	415-416	.	_	_	_	_

#Text=They create huge colonies known as biofilms .
5-1	417-421	They	abstract	giv	coref	10-13[57_0]
5-2	422-428	create	_	_	_	_
5-3	429-433	huge	place[22]	new[22]	_	_
5-4	434-442	colonies	place[22]	new[22]	_	_
5-5	443-448	known	_	_	_	_
5-6	449-451	as	_	_	_	_
5-7	452-460	biofilms	_	_	_	_
5-8	461-462	.	_	_	_	_

#Text=Existence in biofilms is for them more advantageous because biofilm provides protection for their cells , maintains a homeostasis , and creates a barrier that isolates bacteria from the surroundings .
6-1	463-472	Existence	abstract[23]	new[23]	_	_
6-2	473-475	in	abstract[23]	new[23]	_	_
6-3	476-484	biofilms	abstract[23]|substance	new[23]|giv	ana	6-6
6-4	485-487	is	_	_	_	_
6-5	488-491	for	_	_	_	_
6-6	492-496	them	substance	giv	ana	6-14
6-7	497-501	more	_	_	_	_
6-8	502-514	advantageous	_	_	_	_
6-9	515-522	because	_	_	_	_
6-10	523-530	biofilm	substance	giv	coref	8-6
6-11	531-539	provides	_	_	_	_
6-12	540-550	protection	abstract	new	_	_
6-13	551-554	for	_	_	_	_
6-14	555-560	their	substance|object[29]	giv|new[29]	coref|coref	8-3[42_29]|14-1
6-15	561-566	cells	object[29]	new[29]	_	_
6-16	567-568	,	_	_	_	_
6-17	569-578	maintains	_	_	_	_
6-18	579-580	a	abstract[30]	new[30]	_	_
6-19	581-592	homeostasis	abstract[30]	new[30]	_	_
6-20	593-594	,	_	_	_	_
6-21	595-598	and	_	_	_	_
6-22	599-606	creates	_	_	_	_
6-23	607-608	a	object[31]	new[31]	_	_
6-24	609-616	barrier	object[31]	new[31]	_	_
6-25	617-621	that	_	_	_	_
6-26	622-630	isolates	_	_	_	_
6-27	631-639	bacteria	animal	giv	coref	7-6[35_0]
6-28	640-644	from	_	_	_	_
6-29	645-648	the	place[33]	new[33]	_	_
6-30	649-661	surroundings	place[33]	new[33]	_	_
6-31	662-663	.	_	_	_	_

#Text=There is extensive communication between bacteria and the effective horizontal transfer of resistance and virulence genes that make bacteria very resistant .
7-1	664-669	There	_	_	_	_
7-2	670-672	is	_	_	_	_
7-3	673-682	extensive	abstract[34]	new[34]	_	_
7-4	683-696	communication	abstract[34]	new[34]	_	_
7-5	697-704	between	abstract[34]	new[34]	_	_
7-6	705-713	bacteria	abstract[34]|animal[35]	new[34]|giv[35]	coref	7-19[0_35]
7-7	714-717	and	abstract[34]|animal[35]	new[34]|giv[35]	_	_
7-8	718-721	the	abstract[34]|animal[35]|event[36]	new[34]|giv[35]|new[36]	_	_
7-9	722-731	effective	abstract[34]|animal[35]|event[36]	new[34]|giv[35]|new[36]	_	_
7-10	732-742	horizontal	abstract[34]|animal[35]|event[36]	new[34]|giv[35]|new[36]	_	_
7-11	743-751	transfer	abstract[34]|animal[35]|event[36]	new[34]|giv[35]|new[36]	_	_
7-12	752-754	of	abstract[34]|animal[35]|event[36]	new[34]|giv[35]|new[36]	_	_
7-13	755-765	resistance	abstract[34]|animal[35]|event[36]|abstract	new[34]|giv[35]|new[36]|new	coref	17-1[84_0]
7-14	766-769	and	abstract[34]|animal[35]|event[36]	new[34]|giv[35]|new[36]	_	_
7-15	770-779	virulence	abstract[34]|animal[35]|event[36]|abstract|abstract[39]	new[34]|giv[35]|new[36]|new|new[39]	_	_
7-16	780-785	genes	abstract[34]|animal[35]|event[36]|abstract[39]	new[34]|giv[35]|new[36]|new[39]	_	_
7-17	786-790	that	_	_	_	_
7-18	791-795	make	_	_	_	_
7-19	796-804	bacteria	animal	giv	coref	8-3
7-20	805-809	very	_	_	_	_
7-21	810-819	resistant	_	_	_	_
7-22	820-821	.	_	_	_	_

#Text=Thus , bacteria cells in biofilm are more resistant to toxic substances , UV radiation , mechanical damage , bacteriophages , or predators .
8-1	822-826	Thus	_	_	_	_
8-2	827-828	,	_	_	_	_
8-3	829-837	bacteria	animal|object[42]	giv|giv[42]	coref|coref	10-11|18-1[91_42]
8-4	838-843	cells	object[42]	giv[42]	_	_
8-5	844-846	in	object[42]	giv[42]	_	_
8-6	847-854	biofilm	object[42]|substance	giv[42]|giv	coref	10-17[58_0]
8-7	855-858	are	_	_	_	_
8-8	859-863	more	_	_	_	_
8-9	864-873	resistant	_	_	_	_
8-10	874-876	to	_	_	_	_
8-11	877-882	toxic	substance[44]	giv[44]	coref	18-11[94_44]
8-12	883-893	substances	substance[44]	giv[44]	_	_
8-13	894-895	,	substance[44]	giv[44]	_	_
8-14	896-898	UV	substance[44]|place|substance[46]	giv[44]|new|new[46]	_	_
8-15	899-908	radiation	substance[44]|substance[46]	giv[44]|new[46]	_	_
8-16	909-910	,	substance[44]	giv[44]	_	_
8-17	911-921	mechanical	substance[44]|abstract[47]	giv[44]|new[47]	_	_
8-18	922-928	damage	substance[44]|abstract[47]	giv[44]|new[47]	_	_
8-19	929-930	,	substance[44]	giv[44]	_	_
8-20	931-945	bacteriophages	substance[44]|object	giv[44]|new	ana	9-1
8-21	946-947	,	substance[44]	giv[44]	_	_
8-22	948-950	or	substance[44]	giv[44]	_	_
8-23	951-960	predators	substance[44]|animal	giv[44]|new	_	_
8-24	961-962	.	_	_	_	_

#Text=They are also more resistant to the immune system and antibiotics in a human or animal body .
9-1	963-967	They	object	giv	_	_
9-2	968-971	are	_	_	_	_
9-3	972-976	also	_	_	_	_
9-4	977-981	more	_	_	_	_
9-5	982-991	resistant	_	_	_	_
9-6	992-994	to	_	_	_	_
9-7	995-998	the	abstract[51]	new[51]	_	_
9-8	999-1005	immune	abstract[51]	new[51]	_	_
9-9	1006-1012	system	abstract[51]	new[51]	_	_
9-10	1013-1016	and	_	_	_	_
9-11	1017-1028	antibiotics	substance[52]	new[52]	_	_
9-12	1029-1031	in	substance[52]	new[52]	_	_
9-13	1032-1033	a	substance[52]|object[53]	new[52]|new[53]	coref	20-7[103_53]
9-14	1034-1039	human	substance[52]|object[53]	new[52]|new[53]	_	_
9-15	1040-1042	or	substance[52]|object[53]	new[52]|new[53]	_	_
9-16	1043-1049	animal	substance[52]|object[53]	new[52]|new[53]	_	_
9-17	1050-1054	body	substance[52]|object[53]	new[52]|new[53]	_	_
9-18	1055-1056	.	_	_	_	_

#Text=The surface of the material is very quickly occupied by bacteria because the host products create a biofilm on the material that helps to bind the bacteria .
10-1	1057-1060	The	place[54]	new[54]	coref	26-9[0_54]
10-2	1061-1068	surface	place[54]	new[54]	_	_
10-3	1069-1071	of	place[54]	new[54]	_	_
10-4	1072-1075	the	place[54]|object[55]	new[54]|new[55]	coref	10-20[59_55]
10-5	1076-1084	material	place[54]|object[55]	new[54]|new[55]	_	_
10-6	1085-1087	is	_	_	_	_
10-7	1088-1092	very	_	_	_	_
10-8	1093-1100	quickly	_	_	_	_
10-9	1101-1109	occupied	_	_	_	_
10-10	1110-1112	by	_	_	_	_
10-11	1113-1121	bacteria	animal	giv	coref	10-26[60_0]
10-12	1122-1129	because	_	_	_	_
10-13	1130-1133	the	abstract[57]	giv[57]	coref	16-16[78_57]
10-14	1134-1138	host	abstract[57]	giv[57]	_	_
10-15	1139-1147	products	abstract[57]	giv[57]	_	_
10-16	1148-1154	create	_	_	_	_
10-17	1155-1156	a	substance[58]	giv[58]	coref	17-2[83_58]
10-18	1157-1164	biofilm	substance[58]	giv[58]	_	_
10-19	1165-1167	on	substance[58]	giv[58]	_	_
10-20	1168-1171	the	substance[58]|object[59]	giv[58]|giv[59]	_	_
10-21	1172-1180	material	substance[58]|object[59]	giv[58]|giv[59]	_	_
10-22	1181-1185	that	_	_	_	_
10-23	1186-1191	helps	_	_	_	_
10-24	1192-1194	to	_	_	_	_
10-25	1195-1199	bind	_	_	_	_
10-26	1200-1203	the	animal[60]	giv[60]	coref	16-6[75_60]
10-27	1204-1212	bacteria	animal[60]	giv[60]	_	_
10-28	1213-1214	.	_	_	_	_

#Text=This process takes place in five stages , as can be seen in
11-1	1215-1219	This	abstract[61]	new[61]	_	_
11-2	1220-1227	process	abstract[61]	new[61]	_	_
11-3	1228-1233	takes	_	_	_	_
11-4	1234-1239	place	_	_	_	_
11-5	1240-1242	in	_	_	_	_
11-6	1243-1247	five	abstract[62]	new[62]	_	_
11-7	1248-1254	stages	abstract[62]	new[62]	_	_
11-8	1255-1256	,	_	_	_	_
11-9	1257-1259	as	_	_	_	_
11-10	1260-1263	can	_	_	_	_
11-11	1264-1266	be	_	_	_	_
11-12	1267-1271	seen	_	_	_	_
11-13	1272-1274	in	_	_	_	_

#Text=Figure 3
12-1	1275-1281	Figure	abstract[63]	new[63]	_	_
12-2	1282-1283	3	abstract[63]	new[63]	_	_

#Text=.
13-1	1284-1285	.	_	_	_	_

#Text=Biofilms affect many medical applications and are a serious medical problem at the present time .
14-1	1286-1294	Biofilms	substance	giv	ana	15-1
14-2	1295-1301	affect	_	_	_	_
14-3	1302-1306	many	abstract[65]	new[65]	_	_
14-4	1307-1314	medical	abstract[65]	new[65]	_	_
14-5	1315-1327	applications	abstract[65]	new[65]	_	_
14-6	1328-1331	and	_	_	_	_
14-7	1332-1335	are	_	_	_	_
14-8	1336-1337	a	abstract[66]	new[66]	_	_
14-9	1338-1345	serious	abstract[66]	new[66]	_	_
14-10	1346-1353	medical	abstract[66]	new[66]	_	_
14-11	1354-1361	problem	abstract[66]	new[66]	_	_
14-12	1362-1364	at	abstract[66]	new[66]	_	_
14-13	1365-1368	the	abstract[66]|time[67]	new[66]|new[67]	_	_
14-14	1369-1376	present	abstract[66]|time[67]	new[66]|new[67]	_	_
14-15	1377-1381	time	abstract[66]|time[67]	new[66]|new[67]	_	_
14-16	1382-1383	.	_	_	_	_

#Text=They are found , for example , in catheters , stents , contact lenses , and many other implants .
15-1	1384-1388	They	substance	giv	coref	18-6
15-2	1389-1392	are	_	_	_	_
15-3	1393-1398	found	_	_	_	_
15-4	1399-1400	,	_	_	_	_
15-5	1401-1404	for	_	_	_	_
15-6	1405-1412	example	_	_	_	_
15-7	1413-1414	,	_	_	_	_
15-8	1415-1417	in	_	_	_	_
15-9	1418-1427	catheters	object	new	coref	22-5
15-10	1428-1429	,	_	_	_	_
15-11	1430-1436	stents	object	giv	_	_
15-12	1437-1438	,	_	_	_	_
15-13	1439-1446	contact	_	_	_	_
15-14	1447-1453	lenses	object	new	_	_
15-15	1454-1455	,	_	_	_	_
15-16	1456-1459	and	_	_	_	_
15-17	1460-1464	many	object[72]	new[72]	coref	20-1[101_72]
15-18	1465-1470	other	object[72]	new[72]	_	_
15-19	1471-1479	implants	object[72]	new[72]	_	_
15-20	1480-1481	.	_	_	_	_

#Text=Biomaterials at risk of attaching bacteria together with corresponding body fluids and major components of the host products for bacterial growth are classified in Table 1 .
16-1	1482-1494	Biomaterials	substance[73]	new[73]	_	_
16-2	1495-1497	at	substance[73]	new[73]	_	_
16-3	1498-1502	risk	substance[73]|abstract	new[73]|new	coref	17-11[86_0]
16-4	1503-1505	of	_	_	_	_
16-5	1506-1515	attaching	_	_	_	_
16-6	1516-1524	bacteria	animal[75]	giv[75]	_	_
16-7	1525-1533	together	animal[75]	giv[75]	_	_
16-8	1534-1538	with	animal[75]	giv[75]	_	_
16-9	1539-1552	corresponding	animal[75]|substance[76]	giv[75]|new[76]	_	_
16-10	1553-1557	body	animal[75]|substance[76]	giv[75]|new[76]	_	_
16-11	1558-1564	fluids	animal[75]|substance[76]	giv[75]|new[76]	_	_
16-12	1565-1568	and	animal[75]	giv[75]	_	_
16-13	1569-1574	major	animal[75]|abstract[77]	giv[75]|new[77]	_	_
16-14	1575-1585	components	animal[75]|abstract[77]	giv[75]|new[77]	_	_
16-15	1586-1588	of	animal[75]|abstract[77]	giv[75]|new[77]	_	_
16-16	1589-1592	the	animal[75]|abstract[77]|abstract[78]	giv[75]|new[77]|giv[78]	_	_
16-17	1593-1597	host	animal[75]|abstract[77]|abstract[78]	giv[75]|new[77]|giv[78]	_	_
16-18	1598-1606	products	animal[75]|abstract[77]|abstract[78]	giv[75]|new[77]|giv[78]	_	_
16-19	1607-1610	for	animal[75]|abstract[77]|abstract[78]	giv[75]|new[77]|giv[78]	_	_
16-20	1611-1620	bacterial	animal[75]|abstract[77]|abstract[78]|animal|abstract[80]	giv[75]|new[77]|giv[78]|new|giv[80]	_	_
16-21	1621-1627	growth	animal[75]|abstract[77]|abstract[78]|abstract[80]	giv[75]|new[77]|giv[78]|giv[80]	_	_
16-22	1628-1631	are	_	_	_	_
16-23	1632-1642	classified	_	_	_	_
16-24	1643-1645	in	_	_	_	_
16-25	1646-1651	Table	abstract	new	coref	23-1
16-26	1652-1653	1	quantity	new	_	_
16-27	1654-1655	.	_	_	_	_

#Text=The biofilm ’s high resistance to antibacterial agents results in a great risk of infection and therefore creates a very hazardous situation for patient health .
17-1	1656-1659	The	abstract[84]	giv[84]	coref	18-8[93_84]
17-2	1660-1667	biofilm	substance[83]|abstract[84]	giv[83]|giv[84]	coref	19-9[0_83]
17-3	1668-1670	’s	substance[83]|abstract[84]	giv[83]|giv[84]	_	_
17-4	1671-1675	high	abstract[84]	giv[84]	_	_
17-5	1676-1686	resistance	abstract[84]	giv[84]	_	_
17-6	1687-1689	to	abstract[84]	giv[84]	_	_
17-7	1690-1703	antibacterial	abstract[84]|substance[85]	giv[84]|new[85]	_	_
17-8	1704-1710	agents	abstract[84]|substance[85]	giv[84]|new[85]	_	_
17-9	1711-1718	results	_	_	_	_
17-10	1719-1721	in	_	_	_	_
17-11	1722-1723	a	abstract[86]	giv[86]	_	_
17-12	1724-1729	great	abstract[86]	giv[86]	_	_
17-13	1730-1734	risk	abstract[86]	giv[86]	_	_
17-14	1735-1737	of	abstract[86]	giv[86]	_	_
17-15	1738-1747	infection	abstract[86]|event	giv[86]|new	coref	24-18
17-16	1748-1751	and	_	_	_	_
17-17	1752-1761	therefore	_	_	_	_
17-18	1762-1769	creates	_	_	_	_
17-19	1770-1771	a	abstract[88]	new[88]	_	_
17-20	1772-1776	very	abstract[88]	new[88]	_	_
17-21	1777-1786	hazardous	abstract[88]	new[88]	_	_
17-22	1787-1796	situation	abstract[88]	new[88]	_	_
17-23	1797-1800	for	abstract[88]	new[88]	_	_
17-24	1801-1808	patient	abstract[88]|person|abstract[90]	new[88]|new|new[90]	coref	20-8[102_0]
17-25	1809-1815	health	abstract[88]|abstract[90]	new[88]|new[90]	_	_
17-26	1816-1817	.	_	_	_	_

#Text=Microbial cells that live in biofilms have greater resistance to antimicrobial substances than cells that live alone in planktonic form .
18-1	1818-1827	Microbial	object[91]	giv[91]	coref	18-14[0_91]
18-2	1828-1833	cells	object[91]	giv[91]	_	_
18-3	1834-1838	that	_	_	_	_
18-4	1839-1843	live	_	_	_	_
18-5	1844-1846	in	_	_	_	_
18-6	1847-1855	biofilms	substance	giv	coref	23-12
18-7	1856-1860	have	_	_	_	_
18-8	1861-1868	greater	abstract[93]	giv[93]	coref	19-3[97_93]
18-9	1869-1879	resistance	abstract[93]	giv[93]	_	_
18-10	1880-1882	to	abstract[93]	giv[93]	_	_
18-11	1883-1896	antimicrobial	abstract[93]|substance[94]	giv[93]|giv[94]	_	_
18-12	1897-1907	substances	abstract[93]|substance[94]	giv[93]|giv[94]	_	_
18-13	1908-1912	than	abstract[93]|substance[94]	giv[93]|giv[94]	_	_
18-14	1913-1918	cells	abstract[93]|substance[94]|object	giv[93]|giv[94]|giv	_	_
18-15	1919-1923	that	_	_	_	_
18-16	1924-1928	live	_	_	_	_
18-17	1929-1934	alone	_	_	_	_
18-18	1935-1937	in	_	_	_	_
18-19	1938-1948	planktonic	substance[96]	new[96]	_	_
18-20	1949-1953	form	substance[96]	new[96]	_	_
18-21	1954-1955	.	_	_	_	_

#Text=Due to this resistance , the treatment of biofilm infections is very difficult .
19-1	1956-1959	Due	_	_	_	_
19-2	1960-1962	to	_	_	_	_
19-3	1963-1967	this	abstract[97]	giv[97]	_	_
19-4	1968-1978	resistance	abstract[97]	giv[97]	_	_
19-5	1979-1980	,	_	_	_	_
19-6	1981-1984	the	event[98]	new[98]	coref	22-9[0_98]
19-7	1985-1994	treatment	event[98]	new[98]	_	_
19-8	1995-1997	of	event[98]	new[98]	_	_
19-9	1998-2005	biofilm	event[98]|substance|abstract[100]	new[98]|giv|giv[100]	coref|coref	23-9[115_100]|24-15
19-10	2006-2016	infections	event[98]|abstract[100]	new[98]|giv[100]	_	_
19-11	2017-2019	is	_	_	_	_
19-12	2020-2024	very	_	_	_	_
19-13	2025-2034	difficult	_	_	_	_
19-14	2035-2036	.	_	_	_	_

#Text=Infected implants must be removed from the patient ’s body .
20-1	2037-2045	Infected	object[101]	giv[101]	coref	22-1[108_101]
20-2	2046-2054	implants	object[101]	giv[101]	_	_
20-3	2055-2059	must	_	_	_	_
20-4	2060-2062	be	_	_	_	_
20-5	2063-2070	removed	_	_	_	_
20-6	2071-2075	from	_	_	_	_
20-7	2076-2079	the	object[103]	giv[103]	_	_
20-8	2080-2087	patient	person[102]|object[103]	giv[102]|giv[103]	_	_
20-9	2088-2090	’s	person[102]|object[103]	giv[102]|giv[103]	_	_
20-10	2091-2095	body	object[103]	giv[103]	_	_
20-11	2096-2097	.	_	_	_	_

#Text=This procedure is usually expensive and dangerous for patients because surgical procedures can cause other complications .
21-1	2098-2102	This	event[104]	new[104]	_	_
21-2	2103-2112	procedure	event[104]	new[104]	_	_
21-3	2113-2115	is	_	_	_	_
21-4	2116-2123	usually	_	_	_	_
21-5	2124-2133	expensive	_	_	_	_
21-6	2134-2137	and	_	_	_	_
21-7	2138-2147	dangerous	_	_	_	_
21-8	2148-2151	for	_	_	_	_
21-9	2152-2160	patients	person	new	_	_
21-10	2161-2168	because	_	_	_	_
21-11	2169-2177	surgical	event[106]	new[106]	_	_
21-12	2178-2188	procedures	event[106]	new[106]	_	_
21-13	2189-2192	can	_	_	_	_
21-14	2193-2198	cause	_	_	_	_
21-15	2199-2204	other	abstract[107]	new[107]	_	_
21-16	2205-2218	complications	abstract[107]	new[107]	_	_
21-17	2219-2220	.	_	_	_	_

#Text=Millions of implants and catheters are used for treatment every year .
22-1	2221-2229	Millions	object[108]	giv[108]	coref	23-6[114_108]
22-2	2230-2232	of	object[108]	giv[108]	_	_
22-3	2233-2241	implants	object[108]	giv[108]	_	_
22-4	2242-2245	and	object[108]	giv[108]	_	_
22-5	2246-2255	catheters	object[108]|object	giv[108]|giv	_	_
22-6	2256-2259	are	_	_	_	_
22-7	2260-2264	used	_	_	_	_
22-8	2265-2268	for	_	_	_	_
22-9	2269-2278	treatment	event	giv	_	_
22-10	2279-2284	every	_	_	_	_
22-11	2285-2289	year	_	_	_	_
22-12	2290-2291	.	_	_	_	_

#Text=Table 2 shows examples of implants prone to the infections of biofilms .
23-1	2292-2297	Table	object|abstract[113]	giv|new[113]	_	_
23-2	2298-2299	2	abstract[112]|abstract[113]	new[112]|new[113]	_	_
23-3	2300-2305	shows	abstract[112]|abstract[113]	new[112]|new[113]	_	_
23-4	2306-2314	examples	abstract[113]	new[113]	_	_
23-5	2315-2317	of	abstract[113]	new[113]	_	_
23-6	2318-2326	implants	abstract[113]|object[114]	new[113]|giv[114]	_	_
23-7	2327-2332	prone	abstract[113]|object[114]	new[113]|giv[114]	_	_
23-8	2333-2335	to	_	_	_	_
23-9	2336-2339	the	abstract[115]	giv[115]	_	_
23-10	2340-2350	infections	abstract[115]	giv[115]	_	_
23-11	2351-2353	of	abstract[115]	giv[115]	_	_
23-12	2354-2362	biofilms	abstract[115]|substance	giv[115]|giv	_	_
23-13	2363-2364	.	_	_	_	_

#Text=For this reason , new materials are being developed to reduce the risk of biofilm formation and infection .
24-1	2365-2368	For	_	_	_	_
24-2	2369-2373	this	abstract[117]	new[117]	_	_
24-3	2374-2380	reason	abstract[117]	new[117]	_	_
24-4	2381-2382	,	_	_	_	_
24-5	2383-2386	new	object[118]	new[118]	coref	25-1[123_118]
24-6	2387-2396	materials	object[118]	new[118]	_	_
24-7	2397-2400	are	_	_	_	_
24-8	2401-2406	being	_	_	_	_
24-9	2407-2416	developed	_	_	_	_
24-10	2417-2419	to	_	_	_	_
24-11	2420-2426	reduce	_	_	_	_
24-12	2427-2430	the	abstract[119]	new[119]	_	_
24-13	2431-2435	risk	abstract[119]	new[119]	_	_
24-14	2436-2438	of	abstract[119]	new[119]	_	_
24-15	2439-2446	biofilm	abstract[119]|substance|abstract[121]	new[119]|giv|new[121]	_	_
24-16	2447-2456	formation	abstract[119]|abstract[121]	new[119]|new[121]	_	_
24-17	2457-2460	and	abstract[119]	new[119]	_	_
24-18	2461-2470	infection	abstract[119]|abstract	new[119]|giv	_	_
24-19	2471-2472	.	_	_	_	_

#Text=These materials are based on polymer composites or polymers with surfaces modified with an antimicrobial agent .
25-1	2473-2478	These	object[123]	giv[123]	_	_
25-2	2479-2488	materials	object[123]	giv[123]	_	_
25-3	2489-2492	are	_	_	_	_
25-4	2493-2498	based	_	_	_	_
25-5	2499-2501	on	_	_	_	_
25-6	2502-2509	polymer	person|object[125]	new|new[125]	_	_
25-7	2510-2520	composites	object[125]	new[125]	_	_
25-8	2521-2523	or	_	_	_	_
25-9	2524-2532	polymers	object	new	_	_
25-10	2533-2537	with	_	_	_	_
25-11	2538-2546	surfaces	place	new	_	_
25-12	2547-2555	modified	_	_	_	_
25-13	2556-2560	with	_	_	_	_
25-14	2561-2563	an	substance[128]	new[128]	_	_
25-15	2564-2577	antimicrobial	substance[128]	new[128]	_	_
25-16	2578-2583	agent	substance[128]	new[128]	_	_
25-17	2584-2585	.	_	_	_	_

#Text=In addition , other options based on physical surface properties such as surface roughening , or vice versa smooth surface , super hydrophobic , etc. should be considered .
26-1	2586-2588	In	_	_	_	_
26-2	2589-2597	addition	_	_	_	_
26-3	2598-2599	,	_	_	_	_
26-4	2600-2605	other	abstract[129]	new[129]	_	_
26-5	2606-2613	options	abstract[129]	new[129]	_	_
26-6	2614-2619	based	_	_	_	_
26-7	2620-2622	on	_	_	_	_
26-8	2623-2631	physical	abstract[131]	new[131]	_	_
26-9	2632-2639	surface	place|abstract[131]	giv|new[131]	coref	26-13
26-10	2640-2650	properties	abstract[131]	new[131]	_	_
26-11	2651-2655	such	abstract[131]	new[131]	_	_
26-12	2656-2658	as	abstract[131]	new[131]	_	_
26-13	2659-2666	surface	abstract[131]|place|abstract[133]	new[131]|giv|new[133]	coref	26-18[134_0]
26-14	2667-2677	roughening	abstract[131]|abstract[133]	new[131]|new[133]	_	_
26-15	2678-2679	,	abstract[131]	new[131]	_	_
26-16	2680-2682	or	abstract[131]	new[131]	_	_
26-17	2683-2687	vice	abstract[131]	new[131]	_	_
26-18	2688-2693	versa	abstract[131]|place[134]	new[131]|giv[134]	_	_
26-19	2694-2700	smooth	abstract[131]|place[134]	new[131]|giv[134]	_	_
26-20	2701-2708	surface	abstract[131]|place[134]	new[131]|giv[134]	_	_
26-21	2709-2710	,	abstract[131]	new[131]	_	_
26-22	2711-2716	super	abstract[131]|substance[135]	new[131]|new[135]	_	_
26-23	2717-2728	hydrophobic	abstract[131]|substance[135]	new[131]|new[135]	_	_
26-24	2729-2730	,	_	_	_	_
26-25	2731-2735	etc.	_	_	_	_
26-26	2736-2742	should	_	_	_	_
26-27	2743-2745	be	_	_	_	_
26-28	2746-2756	considered	_	_	_	_
26-29	2757-2758	.	_	_	_	_
